Analysts Set Adagene Inc. Sponsored ADR (NASDAQ:ADAG) PT at $8.00

Posted by on May 13th, 2026

Adagene Inc. Sponsored ADR (NASDAQ:ADAG – Get Free Report) has been assigned an average recommendation of “Buy” from the five brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $8.00.

Several research firms have issued reports on ADAG. Guggenheim upped their price target on shares of Adagene from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, April 6th. Wall Street Zen upgraded shares of Adagene to a “hold” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adagene in a research report on Monday, April 20th.

Read Our Latest Stock Report on Adagene

Institutional Trading of Adagene

Several institutional investors have recently added to or reduced their stakes in ADAG. Citadel Advisors LLC bought a new position in shares of Adagene during the third quarter valued at about $80,000. SmartHarvest Portfolios LLC bought a new position in shares of Adagene during the fourth quarter valued at about $73,000. Exome Asset Management LLC bought a new position in shares of Adagene during the fourth quarter valued at about $2,004,000. Marex Group plc bought a new position in shares of Adagene during the second quarter valued at about $47,000. Finally, Fifth Lane Capital LP lifted its holdings in Adagene by 427.3% in the 4th quarter. Fifth Lane Capital LP now owns 145,000 shares of the company’s stock worth $274,000 after buying an additional 117,500 shares during the period. 9.51% of the stock is currently owned by hedge funds and other institutional investors.

Adagene Price Performance

NASDAQ ADAG opened at $3.66 on Friday. The company has a 50-day simple moving average of $3.72 and a two-hundred day simple moving average of $2.70. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.07 and a current ratio of 3.07. Adagene has a 12-month low of $1.30 and a 12-month high of $4.75.

Adagene (NASDAQ:ADAG – Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.04) earnings per share (EPS) for the quarter. The business had revenue of $3.84 million for the quarter. As a group, equities analysts predict that Adagene will post -0.49 earnings per share for the current year.

About Adagene

(Get Free Report)

Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene’s pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.

At the core of Adagene’s research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.

Read More

Analyst Recommendations for Adagene (NASDAQ:ADAG)

Receive News & Ratings for Adagene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagene and related companies with MarketBeat.com's FREE daily email newsletter.